BioPharma Dive September 19, 2024
GC Therapeutics claims it can create off-the-shelf therapies from induced pluripotent stem cells faster and simpler than current methods.
A new company born out of research done by top Harvard genetic scientist George Church is promising to “revolutionize cell therapy.”
The company, GC Therapeutics, announced its launch Thursday with $75 million in financing from investors including Cormorant Asset Management and Mubadala Capital. Its board and list of advisers includes John Maraganore, the founding CEO of Alnylam Pharmaceuticals, and Steve Paul, the former CEO of Karuna Therapeutics, along with three executives representing investors.
GCTx is focused on induced pluripotent stem cells, which are derived from a person’s skin or blood cells and then reprogrammed so they can develop into any type...
Today's Sponsors
Today's Sponsor